Phase 4 N=1,346 Smoking Cessation Intervention: Effectiveness in Primary Care
Tobacco Dependence
Primary: 6 Month Self-reported Abstinence From Smoking — 50; 52; 45; 75 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=103 Smoking Cessation in Alcoholics
Smoking Cessation · Alcohol Consumption
Primary: Number of Smoke-free Patients — 0; 3 participants — p==.111
Phase 4 N=1,504 Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms
Nicotine Dependence
Primary: 7-day Point Prevalence of Smoking, Biochemically (Exhaled CO) Confirmed — 90; 87; 107; 84 participants with<10 ppm exhaled CO
N/A N=34 Youth Smoking Cessation: Therapy +/- "The Patch"
Smoking
Primary: Acceptance of Nicotine Replacement Therapy — 26 participants
N/A N=116 Coping Skills Treatment for Smoking Cessation
Nicotine Dependence
Primary: Number of Participants With Biochemically Verified Smoking Abstinence — 11; 12 Participants
Phase 3 N=750 Disease Management for Smoking Cessation
Smoking Cessation
Primary: 7-day Point Prevalence Abstinence From Cigarettes — 68; 56; 56 Participants — p=0.54
N/A N=1,094 Implementation of Smoking Cessation Within NCI Community Oncology Research Program (NCORP) Sites
Smoking Cessation
Primary: Percentage of Patients With 7-day Sustained Smoking Abstinence Reported in the Patient Survey — 13.0; 13.5 percentage of participants — p=0.865
Phase 4 N=1,270 Smoking Cessation in Hospitalized Smokers
Smoking Cessation
Primary: Percentage of Participants With 30-day Abstinence — 18.0; 23.4; 22.1; 18.7 percentage of participants
Phase 1 N=58 Persistence-Targeted Smoking Cessation
Tobacco Use Disorder
Primary: 7-day Point Prevalence Abstinence — 4; 1 participants
Phase 4 N=112 Smoking Cessation Treatment for Methadone Maintenance Patients
Smoking Cessation · Substance-Related Disorders
Primary: Biochemically Verified Abstinence Verified With Expired Carbon Monoxide (CO) < 8 p.p.m. — 6; 0 participants — p=0.03
Phase 4 N=637 Identifying Optimal Smoking Cessation Intervention Components (Cessation)
Smoking · Smoking Cessation · Nicotine Dependence
Primary: Self-Reported 7-Day Point-Prevalence Abstinence — 208; 209; 201; 216 participants — p=.341
N/A N=606 Smoking Cessation in Rural Hospitals
Smoking Cessation
Primary: Number of Participants With 7-day Point Prevalence Abstinence From Cigarettes, Validated — 57; 48 Participants — p=0.46
Phase 4 N=312 Smoking Cessation Study In Healthy Adolescent Smokers
Smoking Cessation
Primary: 4-Week Continuous Abstinence Rate: Percentage of Participants Who Remained Abstinent From Week 9 Through Week 12 — 20.2; 27.2; 18.0 percentage of participants — p=0.6337
Phase 2 N=49 Smoking Cessation Intervention for Thoracic Patients
Lung Cancer
Primary: Determination of the Feasibility of a Cognitive Behavioral Smoking Cessation Intervention. — 17; 32 participants
N/A N=154 Enhancing a High School Based Smoking Cessation Program
Nicotine Dependence
Primary: Abstinence Rates at the End of Treatment — 35.1; 24.3; 38.6; 36.1 percentage of participants not smoking
Phase 4 N=270 Helping Those With Mental Illness Quit Smoking
Smoking · Nicotine Dependence · Mental Disorders
Primary: Acceptance of Wisconsin Tobacco Quit Line Services — 11; 6; 6 participants
Phase 2 N=246 Selegiline for Smoking Cessation - 1
Nicotine Dependence
Primary: Quit Rate — 18; 15 participants
Phase 3 N=504 Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
Smoking Cessation
Primary: Number of Subjects With Four Week Continuous Quit Rate (CQR) — 105; 22 participants — p=<0.0001
N/A N=122 Smoking Cessation in Menthol Flavored Cigarette Smokers
Tobacco Use Disorder
Primary: Time to Lapse — 1.07; 2.55 days
N/A N=164 Smoking Cessation After Hospitalization for a Cardiopulmonary Illness
Smoking Cessation
Primary: Abstinence From Smoking — 15; 7; 13; 10 percentage of participants
N/A N=300 Varenicline or Nicotine Patch in Promoting Smoking Cessation Among Current Smokers
Tobacco Use Disorder
Primary: Quit Rate — 13; 23 Participants
N/A N=19 Smoking Cessation for Smokers With Sleep Problems
Nicotine Dependence · Cigarette Smoking · Insomnia
Primary: Smoking Abstinence — 1; 2; 1; 0 participants
N/A N=56 Novel Medication as a Potential Smoking Cessation Aid
Tobacco Use Disorder
Primary: Percent of Days of Confirmed Abstinence (Out of 5 Maximum) — 46.9; 42.0 percentage of days non-smoking
N/A N=294 Smoking Cessation Using Motivational Therapy and Varenicline
Smoking · HIV Infections
Primary: To Determine the Safety of Varenicline in PLWH Who Smoke — 13; 38; 3; 4 Participants
N/A N=56 Engaging Patients in Tobacco Cessation Resources in Dental Settings
Smoking
Primary: Percentage of Smokers With Delivery of Brief Interventions and/or Referral to Treatment — 7; 36 Participants
Phase 3 N=128 Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder
Smoking Cessation
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 5; 4; 70; 35 participants
N/A N=51 Smoking Cessation E-Visit
Smoking
Primary: Number of Participants Who Utilized Smoking Cessation Treatment — 15; 3 Participants
N/A N=314 Assessing the Effectiveness of a Pharmacist-delivered Smoking Cessation Program in the State of Qatar
Smoking Cessation
Primary: Self-reported 7-day Point Prevalence Abstinence — 26; 31 Participants
N/A N=158 Innovative Digital Therapeutic for Smoking Cessation
Smoking Cessation · Nicotine Addiction · Drug Addiction
Primary: 30-Day Sustained Abstinence From Smoking — 69; 66; 10; 13 Participants
Phase 4 N=544 Evaluation of Treatments to Improve Smoking Cessation Medication Adherence
Smoking · Smoking Cessation · Adherence
Primary: Self-Reported 7-Day Point-Prevalence Abstinence — 197; 181; 202; 176 participants — p=.011